Complication; Immunosuppression; Mesenchymal stem cells; Organ transplantation; Tolerance
Abstract :
[en] Mesenchymal stromal cells (MSCs) are multipotent and self-renewing cells that reside essentially in the bone marrow as a non-hematopoietic cell population, but may also be isolated from the connective tissues of most organs. MSCs represent a heterogeneous population of adult, fibroblast-like cells characterized by their ability to differentiate into tissues of mesodermal lineages including adipocytes, chondrocytes and osteocytes. For several years now, MSCs have been evaluated for their in vivo and in vitro immunomodulatory and 'tissue reconstruction' properties, which could make them interesting in various clinical settings, and particularly in organ transplantation. This paper aims to review current knowledge on the properties of MSCs and their use in pre-clinical and clinical studies in solid organ transplantation, and particularly in the field of liver transplantation. The first available clinical data seem to show that MSCs are safe to use, at least in the medium-term, but more time is needed to evaluate the potential adverse effects of long-term use. Many issues must be resolved on the correct use of MSCs. Intensive in vitro and pre-clinical research are the keys to a better understanding of the way that MSCs act, and to eventually lead to clinical success.
Disciplines :
Hematology Surgery
Author, co-author :
VANDERMEULEN, Morgan ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs chirurgie
GREGOIRE, Céline ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
BRIQUET, Alexandra ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
LECHANTEUR, Chantal ; Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
DETRY, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Language :
English
Title :
Rationale for the potential use of mesenchymal stromal cells in liver transplantation.
Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295 [PMID: 12475952 DOI:10.1091/ mbc.E02-02-0105]
Toma JG, Akhavan M, Fernandes KJ, Barnabé-Heider F, Sadikot A, Kaplan DR, Miller FD. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001; 3: 778-784 [PMID: 11533656 DOI:10.1038/ncb0901-778]
Hoogduijn MJ, Crop MJ, Peeters AM, Van Osch GJ, Balk AH, Ijzermans JN, Weimar W, Baan CC. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16: 597-604 [PMID: 17784833 DOI:10.1089/scd.2006.0110]
Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B, Tang P, Mao N. Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol 2004; 32: 657-664 [PMID: 15246162 DOI:10.1016/j.exphem.2004.04.001]
Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109: 235-242 [PMID: 10848804]
Fan CG, Tang FW, Zhang QJ, Lu SH, Liu HY, Zhao ZM, Liu B, Han ZB, Han ZC. Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell Transplant 2005; 14: 311-321 [PMID: 16052912]
Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98: 2396-2402 [PMID: 11588036]
Young HE, Mancini ML, Wright RP, Smith JC, Black AC, Reagan CR, Lucas PA. Mesenchymal stem cells reside within the connective tissues of many organs. Dev Dyn 1995; 202: 137-144 [PMID: 7734732 DOI:10.1002/aja.1002020205]
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317 [PMID: 16923606 DOI:10.1080/14653240600855905]
Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 2011; 33: 593-602 [PMID: 21499984 DOI:10.1007/s00281-011-0267-7]
Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398 [PMID: 16123384 DOI:10.1634/stemcells.2005-0008]
Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca JD. Characterization and functionality of cell surface molecules on human mesenchymal stem cells, J Biomed Sci 2003; 10: 228-241 [PMID: 12595759 DOI: 68710]
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ring dén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896 [PMID: 14550804]
François M, Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009; 114: 2632-2638 [PMID: 19654411 DOI:10.1182/blood-2009-02-207795]
Romieu-Mourez R, François M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol 2007; 179: 1549-1558 [PMID: 17641021]
Chan WK, Lau AS, Li JC, Law HK, Lau YL, Chan GC. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol 2008; 36: 1545-1555 [PMID: 18715686 DOI:10.1016/ j.exphem.2008.06.008]
Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577 [PMID: 16293599 DOI: 10.1182/ blood-2005-07-2793]
Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120 [PMID: 16690970 DOI:10.1182/ blood-2005-11-011650]
Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I, Rossi L, Abbate R, Marseglia G, Nannetti G, Torricelli F, Miracco C, Bosi A, Fimiani M, Saccardi R. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008; 300: 115-124 [PMID: 18259766 DOI:10.1007/ s00403-007-0827-9]
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843 [PMID: 11986244]
Angoulvant D, Clerc A, Benchalal S, Galambrun C, Parre A, Bertrand Y, Eljaafari A. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004; 41: 469-476 [PMID: 15299278]
Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, Yacoub MH. Human mesenchymal stem cells induce T cell anergy and downregulate T cell alloresponses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng 2006; 12: 2263-2273 [PMID: 16968166 DOI:10.1089/ten.2006.12.2263]
Liu XJ, Zhang JF, Sun B, Peng HS, Kong QF, Bai SS, Liu YM, Wang GY, Wang JH, Li HL. Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-beta and interleukin-6. Clin Exp Immunol 2009; 158: 37-44 [PMID: 19737229 DOI:10.1111/j.1365-2249.2009.03995.x]
Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, Sportoletti P, Falzetti F, Tabilio A. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36: 309-318 [PMID: 18279718 DOI:10.1016/ j.exphem.2007.11.007]
Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int 2008; 7: 608-614 [PMID: 19073406]
Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184: 5885-5894 [PMID: 20382885 DOI:10.4049/jimmunol.0903143]
Madec AM, Malione R, Afonso G, Ab ou Mrad E, Mesnier A, Eljaafari A, Thivolet C. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52: 1391-1399 [PMID: 19421731 DOI:10.1007/ s00125-009-1374-z]
English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160 [PMID: 19210524 DOI:10.1111/j.1365-2249.2009.03874.x]
Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222 [PMID: 17932417 DOI:10.1634/stemcells.2007-0554]
Rouas-Freiss N, Naji A, Durrbach A, Carosella ED. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 2007; 84: S21-S25 [PMID: 17632407 DOI:10.1097/01. tp.0000269117.32179.1c]
Comoli P, Ginevri F, Macearlo R, Avanzini MA, Marconi M, Groff A, Cometa A, Cioni M, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-1202 [PMID: 18029377 DOI: 10.1093/ndt/gfm740]
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistola V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372 [PMID: 16141348 DOI: 10.1182/blood-2005-07-2657]
Tabera S, Pérez-Simón JA, Díez-Campelo M, Sánchez-Abarca LI, Blanco B, López A, Benito A, Ocio E, Sánchez-Guijo FM, Cañizo C, San Miguel JF. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93: 1301-1309 [PMID: 18641017 DOI:10.3324/haematol.12857]
Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, Martini A. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26: 562-569 [PMID: 18024418 DOI:10.1634/stemcells.2007-0528]
Rasmusson I, Le Blanc K, Sundberg B, Ring dén O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65: 336-343 [PMID: 17386024 DOI:10.1111/j.1365-3083.2007.01905.x]
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85 [PMID: 16099998 DOI:10.1634/stemcells.2004-0359]
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333 [PMID: 17951526 DOI: 10.1182/blood-2007-02-074997]
Rasmusson I, Ring dén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76:1208-1213 [PMID: 14578755 DOI:10.1097/01.TP.0000082540.43730.80]
Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006; 24: 462-471 [PMID: 16109759 DOI: 10.1634/ stemcells.2004-0331]
Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490 [PMID: 16239427 DOI: 10.1182/blood-2005-07-2775]
Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76 [PMID: 17220794 DOI: 10.1097/01.tp.0000244572.24780.54]
Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087 [PMID: 16887966]
Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, Zhu X, Lu C, Liang W, Liao L, Zenke M, Zhao RC. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113: 46-57 [PMID: 18832657 DOI:10.1182/blood-2008-04-154138]
Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49 [PMID: 19098906 DOI:10.1038/nm.1905]
Ren G, Su J, Zhang L, Zhao X, Ling W, L'huillie A, Zhang J, Lu Y, Roberts AI, Ji W, Zhang H, Rabson AB, Shi Y. Species variation in the mechanisms of mesenchymal stem cellmediated immunosuppression. Stem Cells 2009; 27:1954-1962 [PMID: 19544427 DOI:10.1002/stem.118]
Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621 [PMID: 15001472 DOI:10.1182/blood-2003-11-3909]
Hainz U, Jürgens B, Heitger A. The role of indoleamine 2,3-dioxygenase in transplantation. Transpl Int 2007; 20: 118-127 [PMID: 17239019 DOI:10.1111/ j.1432-2277.2006.00370.x]
Bauer TM, Jiga LP, Chuang JJ, Randazzo M, Opelz G, Terness P. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 2005; 18: 95-100 [PMID: 15612990 DOI:10.1111/ j.1432-2277.2004.00031.x]
Gieseke F, Schütt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaRl signaling and IDO expression. Blood 2007; 110: 2197-2200 [PMID: 17522338 DOI:10.1182/ blood-2007-04-083162]
Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234 [PMID: 16985180 DOI:10.1182/ blood-2006-02-002246]
Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150 [PMID: 18371435 DOI:10.1016/ j.stem.2007.11.014]
Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774 [PMID: 15459668 DOI:10.1038/nri1457]
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269 [PMID: 2827174]
Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternalfetal tolerance to tissue acceptance. Adv Immunol 2003; 81: 199-252 [PMID: 14711057]
Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier G, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84: 231-237 [PMID: 17667815 DOI:10.1097/01.tp.0000267918.07906.08]
Matysiak M, Orlowski W, Fortak-Michalska M, Jurewicz A, Selmaj K. Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J Neuroimmunol 2011; 233: 106-111 [PMID: 21354631 DOI:10.1016/ j.jneuroim.2010.12.004]
Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Thl cell differentiation and Th17 cell expansion. Nat Med 2009; 15: 633-640 [PMID: 19465928 DOI: 10.1038/nm.1968]
Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, Nam HY, Kim YH, Kim B, Park CG. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 2009; 41: 315-324 [PMID: 19307751 DOI:10.3858/emm.2009.41.5.035]
Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104: 11002-11007 [PMID: 17569781 DOI:10.1073/ pnas.0704421104]
Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28: 2229-2238 [PMID: 20945332 DOI:10.1002/stem.544]
Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem 2007; 20: 867-876 [PMID: 17982269 DOI:10.1159/000110447]
Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 2010; 285: 26211-26222 [PMID: 20554518 DOI:10.1074/jbc.M110.119917]
Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, Leiner I, Li MO, Frenette PS, Pamer EG. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011; 34: 590-601 [PMID: 21458307 DOI: 10.1016/j.immuni.2011.02.016]
Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, Dahlke MH. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 2010; 10: 1496-1500 [PMID: 20619384 DOI:10.1016/j.intimp.2010.06.019]
Tropel P, Platet N, Platel JC, Noël D, Albrieux M, Benabid AL, Berger F. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 2868-2876 [PMID: 16902198 DOI:10.1634/stemcefls.2005-0636]
Rose RA, Keating A, Backx PH. Do mesenchymal stromal cells transdifferentiate into functional cardiomyocytes? Circ Res 2008; 103: e120 [PMID: 18948624 DOI:10.1161/CIRCRESAHA.108.186908]
Taléns-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, Castell JV, Gómez-Lechón MJ. Human mesenchymal stem cells from adipose tissue: Differentiation into hepatic lineage. Toxicol In Vitro 2007; 21: 324-329 [PMID: 17045453 DOI: 10.1016/j.tiv.2006.08.009]
Seo MJ, Suh SY, Bae YC, Jung JS. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun 2005; 328: 258-264 [PMID: 15670778 DOI:10.1016/j.bbrc.2004.12.158]
Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109: 1291-1302 [PMID: 12021244 DOI:10.1172/JCI15182]
Minguell JJ, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp Biol Med (Maywood) 2006; 231: 39-49 [PMID: 16380643]
Kunter U, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, Floege J. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 2202-2212 [PMID: 16790513 DOI: 10.1681/ASN.2005080815]
Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14: 1035-1041 [PMID: 15547670]
Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313 [PMID: 10086387 DOI:10.1038/6529]
Zeinaloo A, Zanjani KS, Bagheri MM, Mohyeddin-Bonab M, Monajemzadeh M, Arjmandnia MH. Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatr Transplant 2011; 15: E183-E186 [PMID: 20880092 DOI:10.1111/ j.1399-3046.2010.01366.x]
Yang Z, Zhang F, Ma W, Chen B, Zhou F, Xu Z, Zhang Y, Zhang D, Zhu T, Wang L, Wang H, Ding Z, Zhang Y. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther 2010; 28: 380-385 [PMID: 20337639 DOI:10.1111/j.1755-5922.2009.00116.x]
Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, Perez SA, Voridis EM, Papamichail M. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65: 321-329 [PMID: 15954106 DOI: 10.1002/ccd.20406]
Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427 [PMID: 15784733 DOI:10.1182/blood-2004-09-3507]
Von Lüttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R, Huss R, Nelson PJ. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 2005; 14: 329-336 [PMID: 15969628 DOI: 10.1089/scd.2005.14.329]
Forte G, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V, Fiaccavento R, Carotenuto F, De Vito P, Bal dini PM, Prat M, Di Nardo P. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006; 24: 23-33 [PMID: 16100005 DOI:10.1634/ stemcells.2004-0176]
Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors, J Cell Biol 2007; 177: 489-500 [PMID: 17470632 DOI:10.1083/jcb.200608093]
Fiedler J, Röderer G, Günther KP, Brenner RE. BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem 2002; 87: 305-312 [PMID: 12397612 DOI:10.1002/jcb.10309]
Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108: 863-868 [PMID: 12900340 DOI:10.1161/01. CIR.0000084828.50310.6A]
Mahmood A, Lu D, Lu M, Chopp M. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003; 53: 697-702; discussion 702-3 [PMID: 12943585]
Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon G, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244-255 [PMID: 11166464]
Popp FC, Slowik P, Eggenhofer E, Renner P, Lang SA, Stoeltzing O, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007; 25: 639-645 [PMID: 17110617 DOI:10.1634/stem-cells.2006-0515]
Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95 [PMID: 15219514 DOI:10.1016/j.amjcard.2004.03.034]
Prockop DJ. "Sternness" does not explain the repair of many tissues by mesenchymal stem/ multipotent stromal cells (MSCs). Clin Pharmacol Ther 2007; 82: 241-243 [PMID: 17700588 DOI:10.1038/sj.clpt.6100313]
Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354: 700-706 [PMID: 17257581 DOI:10.1016/j.bbrc.2007.01.045]
Kachgal S, Putnam AJ. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. Angiogenesis 2011; 14: 47-59 [PMID: 21104120 DOI:10.1007/ S10456-010-9194-9]
Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318-324 [PMID: 19023885 DOI: 10.1002/path.2469]
Erpicum P, Detry O, Weekers L, Bonvoisin C, Lechanteur C, Briquet A, Béguin Y, Krzesinski JM, Jouret F. Mesenchymal stromal cell therapy in conditions of renal ischaemia/ reperfusion. Nephrol Dial Transplant 2014; 29: 1487-1493 [PMID: 24516234 DOI:10.1093/ndt/gft538]
Tögel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183 [PMID: 20186233 DOI:10.1038/nrneph.2009.229]
Donizetti-Oliveira C, Seme do P, Burgos-Silva M, Cenedeze MA, Malheiros DM, Reis MA, Pacheco-Silva A, Câmara NO. Adipose tissue-derived stem cell treatment prevents renal disease progression. Cell Transplant 2012; 21: 1727-1741 [PMID: 22305061 DOI:10.3727/096368911X623925]
van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643 [PMID: 18395843 DOI:10.1002/hep.22236]
Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-1205 [PMID: 19455046 DOI:10.1097/ MEG.0b013e32832a1f6c]
Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, Bashtar M, Ghavamzadeh A, Malekzadeh R. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int 2013; 33: 1490-1496 [PMID: 23763455 DOI: 10.1111 /liv.12228]
Eltzschig HK, Eckle T. Ischemia and reperfusion-from renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14: 1035-1041 [PMID: 15547670]
Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313 [PMID: 10086387 DOI:10.1038/6529]
Zeinaloo A, Zanjani KS, Bagheri MM, Mohyeddin-Bonab M, Monajemzadeh M, Arjmandnia MH. Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatr Transplant 2011; 15: E183-E186 [PMID: 20880092 DOI:10.1111/ j.1399-3046.2010.01366.x]
Yang Z, Zhang F, Ma W, Chen B, Zhou F, Xu Z, Zhang Y, Zhang D, Zhu T, Wang L, Wang H, Ding Z, Zhang Y. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther 2010; 28: 380-385 [PMID: 20337639 DOI:10.1111/j.1755-5922.2009.00116.x]
Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, Perez SA, Voridis EM, Papamichail M. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65: 321-329 [PMID: 15954106 DOI:10.1002/ccd.20406]
Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427 [PMID: 15784733 DOI:10.1182/blood-2004-09-3507]
Von Lüttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R, Huss R, Nelson PJ. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 2005; 14: 329-336 [PMID: 15969628 DOI:10.1089/scd.2005.14.329]
Forte G, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V, Fiaccavento R, Carotenuto F, De Vito P, Bal dini PM, Prat M, Di Nardo P. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006; 24: 23-33 [PMID: 16100005 DOI:10.1634/ stemcells.2004-0176]
Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors, J Cell Biol 2007; 177: 489-500 [PMID: 17470632 DOI:10.1083/jcb.200608093]
Fiedler J, Röderer G, Günther KP, Brenner RE. BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem 2002; 87: 305-312 [PMID: 12397612 DOI:10.1002/jcb.10309]
Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108: 863-868 [PMID: 12900340 DOI:10.1161/01. CIR.0000084828.50310.6A]
Mahmood A, Lu D, Lu M, Chopp M. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003; 53: 697-702; discussion 702-3 [PMID: 12943585]
Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon G, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244-255 [PMID: 11166464]
Popp FC, Slowik P, Eggenhofer E, Renner P, Lang SA, Stoeltzing O, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007; 25: 639-645 [PMID: 17110617 DOI:10.1634/stem-cells.2006-0515]
Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95 [PMID: 15219514 DOI:10.1016/j.amjcard.2004.03.034]
Prockop DJ. "Sternness" does not explain the repair of many tissues by mesenchymal stem/ multipotent stromal cells (MSCs). Clin Pharmacol Ther 2007; 82: 241-243 [PMID: 17700588 DOI:10.1038/sj.clpt.6100313]
Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354: 700-706 [PMID: 17257581 DOI: 10.1016/j.bbrc.2007.01.045]
Kachgal S, Putnam AJ. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. Angiogenesis 2011; 14: 47-59 [PMID: 21104120 DOI:10.1007/ S10456-010-9194-9]
Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318-324 [PMID: 19023885 DOI: 10.1002/path.2469]
Erpicum P, Detry O, Weekers L, Bonvoisin C, Lechanteur C, Briquet A, Beguin Y, Krzesinski JM, Jouret F. Mesenchymal stromal cell therapy in conditions of renal ischaemia/ reperfusion. Nephrol Dial Transplant 2014; 29: 1487-1493 [PMID: 24516234 DOI:10.1093/ndt/gft538]
Tögel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183 [PMID: 20186233 DOI:10.1038/nrneph.2009.229]
van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643 [PMID: 18395843 DOI:10.1002/hep.22236]
Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-1205 [PMID: 19455046 DOI:10.1097/ MEG.0b013e32832a1f6c]
Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, Bashtar M, Ghavamzadeh A, Malekzadeh R. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int 2013; 33:1490-1496 [PMID: 23763455 DOI: 10.1111/liv.12228]